Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › efavirenz

efavirenz

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of efavirenz

36 trials tracked of efavirenz: 20 in phase 3 or 4 and 4 with published results. The most-cited published study has 6953 citations.

36Trials tracked
20Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 12 Phase 3 8 Phase 2 6 Phase 1 4 Other / NA 6
  1. Phase 3 Preventing Sexual Transmission of HIV With Anti-HIV Drugs Completed · 6,953 cited
  2. Phase 3 Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth Completed · 1,421 cited
  3. Phase 3 Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women Completed · 51 cited
  4. Phase 4 Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Completed · 46 cited
  5. Phase 4 CYP2B6 Genetics and Drug Interactions in Healthy Volunteers Completed
  6. Phase 4 Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients Completed
Show 30 more trials
  1. Phase 4 Mechanisms of Lipodystrophy in HIV-Infected Pateints Completed
  2. Phase 4 Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection Completed
  3. Phase 4 Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress Completed
  4. Phase 4 Cryptococcal Optimal ART Timing Trial Completed
  5. Phase 4 REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment Completed
  6. Phase 4 HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV Completed
  7. Phase 4 Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings Completed
  8. Phase 4 Antiretroviral Therapy for Advanced HIV Disease in South Africa Completed
  9. Phase 4 Sustiva Levels With Use of a Gel Capsule Completed
  10. Phase 3 Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) Completed
  11. Phase 3 A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment Completed
  12. Phase 3 TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine. Completed
  13. Phase 3 Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults Completed
  14. Phase 3 TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors Completed
  15. Phase 2 Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected Completed
  16. Phase 2 A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects Completed
  17. Phase 2 Efavirenz in Treating Patients With Metastatic Prostate Cancer Completed
  18. Phase 2 A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines Completed
  19. Phase 2 A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007) Completed
  20. Phase 2 Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants Completed
  21. Phase 1 Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz Completed
  22. Phase 1 A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz Completed
  23. Phase 1 A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants Completed
  24. Phase 1 A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants Completed
  25. N/A Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics Completed
  26. N/A Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities Completed
  27. N/A Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy Completed
  28. N/A Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers Completed
  29. N/A Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection Completed
  30. N/A Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy Completed

Showing the 36 most-cited and recently-updated of 36 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
INSTI switching linked to higher metabolic risk in people with HIV
Diabetes & Endocrinology RCT
INSTI switching linked to higher metabolic risk in people with HIV Switching HIV meds raises diabetes risk but not heart attack danger
A global cohort study found that switching to integrase inhibitors increased risks for obesity, diabetes, and hypertension, but not MACE, ov…
Switching HIV medication to a newer class may raise the risk of diabetes and weight gain, but it does not appear to increase the risk of hea…
May 2, 2026
HIV-1 resistance patterns vary by prior regimen and geographic region in this substudy
Infectious Disease RCT
HIV-1 resistance patterns vary by prior regimen and geographic region in this substudy HIV drug resistance patterns vary by region and prior treatment history
This substudy examined HIV-1 drug resistance mutations in people failing first-line therapy across 14 countries.
HIV drug resistance varies by region and prior treatment. Subtype C dominates, but resistance to common drugs is high. This matters for choo…
May 1, 2026
Target trial emulation in Johannesburg shows dolutegravir associated with greater weight and blood pressure increases versus efavirenz
Infectious Disease RCT
Target trial emulation in Johannesburg shows dolutegravir associated with greater weight and blood pressure increases versus efavirenz New HIV drug linked to higher weight and blood pressure in South Africa
This target trial emulation compared dolutegravir to efavirenz in 2930 treatment-naive individuals in Johannesburg, South Africa.
People starting a new HIV drug in South Africa gained more weight and saw higher blood pressure than those on an older treatment.
May 1, 2026
Switching from EFV/TDF/3TC to B/F/TAF or DTG/3TC in virologically suppressed PLWH shows no significant between-group metabolic differences over 24 months
Drug Pipeline Cohort
Switching from EFV/TDF/3TC to B/F/TAF or DTG/3TC in virologically suppressed PLWH shows no significant between-group metabolic differences over 24 months Switching HIV drugs showed similar metabolic changes over two years in this real-world study
This retrospective real-world study evaluated 326 virologically suppressed persons with HIV (PLWH) switching from efavirenz/tenofovir disopr…
Switching HIV drugs caused similar weight gain and metabolic shifts over two years, meaning lifestyle factors matter more than the specific …
Frontiers Apr 18, 2026
Nevirapine plus lamivudine and zidovudine improved lymphocyte counts and reduced adverse effects versus efavirenz in HIV patients
Infectious Disease RCT
Nevirapine plus lamivudine and zidovudine improved lymphocyte counts and reduced adverse effects versus efavirenz in HIV patients New HIV drug combo showed fewer side effects and better immune markers in small trial
This randomized controlled trial enrolled 100 patients with HIV/AIDS in a hospital setting.
A new HIV drug combo boosted immune cells and caused fewer side effects than the standard alternative in a recent trial.
NEJM Apr 14, 2026